MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM

Autor: Casaletto, Jessica B., Geddie, Melissa L., Abu-Yousif, Adnan O., Masson, Kristina, Fulgham, Aaron, Boudot, Antoine, Maiwald, Tim, Kearns, Jeffrey D., Kohli, Neeraj, Su, Stephen, Razlog, Maja, Raue, Andreas, Kalra, Ashish, Håkansson, Maria, Logan, Derek T., Welin, Martin, Chattopadhyay, Shrikanta, Harms, Brian D., Nielsen, Ulrik B., Schoeberl, Birgit, Lugovskoy, Alexey A., MacBeath, Gavin

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America, 2019 Apr 01. 116(15), 7533-7542.

Externí odkaz: https://www.jstor.org/stable/26701413

Inhibition of the Anaphase-Promoting Complex by the Xnf7 Ubiquitin Ligase

Autor: Casaletto, Jessica B., Nutt, Leta K., Wu, Qiju, Moore, Jonathan D., Etkin, Laurence D., Jackson, Peter K., Hunt, Tim, Kornbluth, Sally

Publikováno v: The Journal of Cell Biology, 2005 Apr 01. 169(1), 61-71.

Externí odkaz: https://www.jstor.org/stable/3658139

Spatial regulation of receptor tyrosine kinases in development and cancer.

Autor: Casaletto, Jessica B.¹, McClatchey, Andrea I.¹

Publikováno v: Nature Reviews Cancer. Jun2012, Vol. 12 Issue 6, p387-400. 14p.

Ezrin-mediated apical integrity is required intestinal homeostasis.

Autor: Casaletto, Jessica B., Saotome, Ichiko, Curto, Marcello, McClatchey, Andrea I.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America; 7/19/2011, Vol. 108 Issue 29, p11924-11929, 6p

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.

Autor: Subbiah V; The University of Texas MD Anderson Cancer Center, Houston, Texas., Sahai V; University of Michigan, Ann Arbor, Michigan., Maglic D; Relay Therapeutics, Inc., Cambridge, Massachusetts., Bruderek K; Relay Therapeutics, Inc., Cambridge, Massachusetts., Touré BB; Relay Therapeutics, Inc., Cambridge, Massachusetts., Zhao S; Relay Therapeutics, Inc., Cambridge, Massachusetts., Valverde R; Relay Therapeutics, Inc., Cambridge, Massachusetts., O'Hearn PJ; Relay Therapeutics, Inc., Cambridge, Massachusetts., Moustakas DT; Relay Therapeutics, Inc., Cambridge, Massachusetts., Schönherr H; Relay Therapeutics, Inc., Cambridge, Massachusetts., Gerami-Moayed N; Relay Therapeutics, Inc., Cambridge, Massachusetts., Taylor AM; Relay Therapeutics, Inc., Cambridge, Massachusetts., Hudson BM; Relay Therapeutics, Inc., Cambridge, Massachusetts., Houde DJ; Relay Therapeutics, Inc., Cambridge, Massachusetts., Pal D; Relay Therapeutics, Inc., Cambridge, Massachusetts., Foster L; Relay Therapeutics, Inc., Cambridge, Massachusetts., Gunaydin H; Relay Therapeutics, Inc., Cambridge, Massachusetts., Ayaz P; D. E. Shaw Research, New York, New York., Sharon DA; D. E. Shaw Research, New York, New York., Goyal L; Massachusetts General Hospital, Boston, Massachusetts., Schram AM; Memorial Sloan Kettering Cancer Center, New York, New York., Kamath S; The Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio., Sherwin CA; Relay Therapeutics, Inc., Cambridge, Massachusetts., Schmidt-Kittler O; Relay Therapeutics, Inc., Cambridge, Massachusetts., Jen KY; Relay Therapeutics, Inc., Cambridge, Massachusetts., Ricard F; Relay Therapeutics, Inc., Cambridge, Massachusetts., Wolf BB; Relay Therapeutics, Inc., Cambridge, Massachusetts., Shaw DE; D. E. Shaw Research, New York, New York.; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York., Bergstrom DA; Relay Therapeutics, Inc., Cambridge, Massachusetts., Watters J; Relay Therapeutics, Inc., Cambridge, Massachusetts., Casaletto JB; Relay Therapeutics, Inc., Cambridge, Massachusetts.

Publikováno v: Cancer discovery [Cancer Discov] 2023 Sep 06; Vol. 13 (9), pp. 2012-2031.